COMP <GO>
MEDP vs INCY // ALTMAN Z-SCORE & DEBT/EQUITY
Medpace Holdings Inc. (NASDAQ) VS. Incyte Corp. (NASDAQ) • 15-METRIC TALLY: MEDP 1
— INCY 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: INCY
LAST: $652.01 (-3.77%) • MKT CAP: $18.95B
balance-sheet
9.13
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
balance-sheet
10.04
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDP VS. INCY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDP | INCY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 92.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.90% | 42.40% | -14.50 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.0x | 12.5x | +21.50 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 3.60% | 4.99% | -1.39 | INCY | /fcf-yield <GO> |
| Operating Margin | 21.10% | 29.50% | -8.40 | INCY | /operating-margins <GO> |
| Net Profit Margin | 17.80% | 25.00% | -7.20 | INCY | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 21.20% | -1.20 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 9.13 | 10.04 | -0.91 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.2 | 50.0 | +11.20 | MEDP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.01 | -0.01 | INCY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.3x | 15.5x | +19.80 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.95B | $23.68B | -$4.72B | INCY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDP REV | INCY REV | MEDP GROSS % | INCY GROSS % | MEDP FCF | INCY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $5.14B | — | 92.8% | $681.9M | $1.18B |
| FY 2024 | $2.11B | $4.24B | — | 92.6% | $572.3M | $144.5M |
| FY 2023 | $1.89B | $3.70B | — | — | $348.5M | $330.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDP // BETA 1.00
INCY // BETA 1.01